Table 1.
Vaccine type | Global |
Low income countries |
Lower-middle income countries |
Upper-middle income countries |
High income countries |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2019 | 2020 | 2021 | 2019 | 2020 | 2021 | 2019 | 2020 | 2021 | 2019 | 2020 | 2021 | 2019 | 2020 | 2021 | |
BCG (n = 157) | 14.3 | 17.8 | 19.3 | 4.4 | 4.5 | 5.7 | 7.2 | 9.5 | 11.1 | 2.1 | 3.5 | 2.2 | 0.6 | 0.3 | 0.3 |
DTP1 (n = 195) | 13.0 | 16.3 | 17.9 | 3.7 | 4.1 | 4.8 | 7.2 | 10.0 | 10.7 | 1.8 | 1.9 | 2.1 | 0.3 | 0.3 | 0.3 |
DTP3 (n = 195) | 18.8 | 22.6 | 24.7 | 5.3 | 5.8 | 6.8 | 10.4 | 13.1 | 14.2 | 2.4 | 2.9 | 2.9 | 0.7 | 0.8 | 0.8 |
Pol3 (n = 195) | 18.6 | 23.2 | 25.3 | 5.2 | 5.8 | 6.8 | 10.7 | 13.6 | 14.7 | 2.0 | 3.0 | 3.0 | 0.7 | 0.8 | 0.8 |
RCV1 (n = 171) | 9.0 | 11.7 | 12.9 | 0.9 | 1.0 | 1.0 | 5.6 | 7.9 | 9.1 | 1.7 | 1.9 | 2.0 | 0.8 | 0.9 | 0.8 |
MCV1 (n = 195) | 18.8 | 21.9 | 24.0 | 6.4 | 6.8 | 7.7 | 9.6 | 11.8 | 13.2 | 2.0 | 2.4 | 2.3 | 0.8 | 0.9 | 0.8 |
MCV2 (n = 177) | 30.0 | 28.8 | 29.3 | 6.4 | 6.2 | 6.3 | 18.4 | 17.6 | 18.5 | 4.2 | 4.0 | 3.5 | 1.0 | 1.0 | 1.0 |
HepB3 (n = 190) | 19.6 | 22.7 | 24.8 | 5.3 | 5.8 | 6.8 | 10.5 | 13.1 | 14.2 | 2.9 | 2.8 | 2.8 | 0.9 | 1.0 | 1.0 |
Hib3 (n = 192) | 18.8 | 22.5 | 24.6 | 5.3 | 5.8 | 6.8 | 10.5 | 13.1 | 14.2 | 2.2 | 2.7 | 2.7 | 0.8 | 0.9 | 0.9 |
PCV3 (n = 144) | 41.1 | 41.3 | 42.0 | 4.4 | 4.9 | 5.7 | 33.0 | 31.4 | 31.2 | 2.6 | 3.5 | 3.6 | 1.1 | 1.5 | 1.5 |
RotaC (n = 102) | 26.6 | 19.1 | 18.8 | 6.8 | 6.1 | 5.9 | 14.8 | 8.2 | 8.1 | 3.1 | 3.0 | 3.1 | 1.9 | 1.8 | 1.7 |
Notes: BCG, Bacillus Calmette-Guérin vaccine; DTP, Diphtheria-tetanus-pertussis vaccine; Pol, Polio vaccine; RCV1, Rubella-containing vaccine; MCV, Measles-containing vaccine; HepB, Hepatitis B vaccine; Hib, Haemophilus influenzae type b vaccine; PCV, Pneumococcal conjugate vaccine, RotaC, Completed rotavirus vaccine.
Data source: WHO-UNICEF Estimates of National Immunization Coverage (WUENIC): 2021 revision.